2026-09-14T08:34:08-07:00 2025-12-31 743216978 Nawrocki Smith LLP 100 Motor Parkway Suite 580 Hauppauge NY 11788 990 2025-01-01 851199264 PRECEDE FOUNDATION INC PREC 9412637968 58 Deer Run Road Red Hook NY 12571 Margaret Caspler CEO 2026-09-14 true Christopher Angotta P02394428 6317569500 2025 Margaret Caspler 58 Deer Run Road Red Hook NY 12571 2378285 false X www.precedefoundation.org X 2020 NY TO SUPPORT THE EFFORTS OF THE PANCREATIC CANCER EARLY DETECTION PROGRAM CONSORTIUM. THE CONSORTIUM IS AN INTERNATIONAL COLLABORATIVE EFFORT, CURRENTLY COMPRISED OF 35 HOSPITALS AND EDUCATIONAL INSTITUTIONS, DESIGNED TO TRANSFER THE LANDSCAPE OF PANCREATIC CANCER RISK ASSESSMENT, EARLY DETETCTION AND PREVENTION. 13 13 3 13 0 1133212 1378810 53550 334583 0 59135 349478 1245897 2062871 0 0 445517 301110 0 265769 1126130 1585548 1571647 1886658 -325750 176213 606955 749645 47821 14298 559134 735347 TO SUPPORT THE EFFORTS OF THE PANCREATIC CANCER EARLY DETECTION PROGRAM CONSORTIUM. THE CONSORTIUM IS AN INTERNATIOANL COLLABORATIVE EFFORT, CURRENTLY COMPRISED OF 35 HOSPITALS AND EDUCATIONAL INSTITUTIONS, DESIGNED TO TRANSFER THE LANDSCAPE OF PANCREATIC CANCER RISK ASSESSMENT, EARLY DETETCTION AND PREVENTION. false false 1544674 The PRECEDE Foundation supports the work being done by 65 academic medical centers around the world that are collaborating on early detection for pancreatic cancer.The Expenses associated with the program include operating a central data repository. PRECEDE Foundation contracts with an outside vendor that specializes in this activity - Arbor Research. Arbor is headquartered in Michigan and is reponsible for onboarding new medical centers, monitoring data completeness and quality,providing analytic support, managing the study IRB, and managing the data registry. Total 2025 expenses for Arbor Research were $605,407.The other major expense is for the Biospecimen repository which receives and stores blood samples for study participants who are part of industry sponsor studies seeking to validate new biomarker assays for pancreatic cancer. PRECEDE Foundation contracts with Azenta Life Sciences to function as the PRECEDE Biorespository. Total 2025 expenses for Azenta were $99,674.PRECEDE Foundation also supports the work being done at each medical center in support of the study. This includes the cost of a research coordinator at each site, the use of a genetic counselor to enroll, consent and screen participants and a data analyst to enter clinical and demographic data for each participant. Total payments to sites in 2025 were $124,170.To-Date program outcomes include:1) conducting a prospective, longitudial clinical validation study for ClearNote Health's early detection blood test - Avantect.2) working with Immunovia to design, devvelop and implement their clinical validation study for the PancreaSure test.3) working with BT Genomics/Singlera on the design of the clinical validation study for the BT Reveal Early Pancreatic Cancer test.4) we have already identified 42 cased of pancreatic ductal adenocarcinoma, 36 of which have early stage disease with an 87% 5-year survival rate. We have also detected 155 other cancers at various stages.5) we hosted an annual meeting with 175 of the principal investigators, other researchers and industry experts to exchange information, review progress, address new developments and design new areas of study to achieve the goal of early detection and a 50% survival rate for pancreatic cancer. 1544674 true true false false false false false false false false false false false false false true true false false false false false false false true false false false false true false false false false false false false false false false false false false false false false false true 10 0 true 3 true false false false false false true true false 0 false false false false false false false X 13 13 false false false false false false false true true false false true true true true true true true true false NY X Debbi Brandel 6318835150 58 Deer Run Road Red Hook NY 12571 Debbie Brandel COO 40.00 0.00 X 176100 0 0 Ron Horvat Former CEO 40.00 0.00 X 95184 0 0 Margaret Caspler President & CEO 40.00 0.00 X 29323 0 0 Jamie Brickell Chairman 1.00 0.00 X X 0 0 0 Victoria Manax Board Member 1.00 0.00 X 0 0 0 Lyle Jackson Board Member 1.00 0.00 X 0 0 0 Doug Frankel Vice Chairman 1.00 0.00 X 0 0 0 Michael Gershenson Board Member 1.00 0.00 X 0 0 0 Alexander Elawadi Board Member 1.00 0.00 X 0 0 0 Tracy Chen Board Member 1.00 0.00 X 0 0 0 Kelly Feehan Board Member 1.00 0.00 X 0 0 0 Brad Fomon Board Member 1.00 0.00 X 0 0 0 Paul Kurywchak Board Member 1.00 0.00 X 0 0 0 Mike Martinson Board Memebr 1.00 0.00 X 0 0 0 Mike Nall Board Member 1.00 0.00 X 0 0 0 Kiran Chapman Board Member 1.00 0.00 X 0 0 0 300607 1 false true false Arbor Research Collaborative for Health 3989 Research Park Dr Ann Arbor MI 48108 Research 605407 1 39454 1339356 1378810 Program Service 900099 334583 334583 334583 0 0 0 0 0 664892 39454 315414 349478 0 0 0 2062871 334583 0 0 0 0 205423 154067 20542 30814 0 95687 71766 9569 14352 0 0 0 0 0 0 0 0 0 105081 78811 26270 111627 83720 27907 64950 64950 0 0 0 55626 55626 0 0 0 0 0 18576 18576 Arbor 605407 605407 MISCELLANEOUS 198337 178503 19834 Precede Fundraiser 192696 192696 Staffing 133170 133170 100078 100078 1886658 1544674 76215 265769 475442 149665 436354 0 131513 161542 0 0 0 0 0 0 0 0 0 0 2084 606955 749645 47821 14298 47821 14298 X 559134 735347 559134 735347 606955 749645 176213 X false true X true false X 241163 139381 140864 1133212 1378810 3033430 0 0 241163 139381 140864 1133212 1378810 3033430 252993 2780437 0 0 0 3033430 388133 0.91660 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 2062871 2062871 2062871 1886658 1886658 1886658 Part X : FIN48 Footnote The Organization recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Management has determined that the Organization had no uncertain tax positions that would require financial statement recognition. The Organization is no longer subject to examination by the applicable taxing jurisdictions for tax years prior to 2022 false Gala 704346 39454 664892 92390 223024 704346 39454 664892 92390 223024 315414 349478 X X false false false false false false false false false Debbie Brandel COO 166100 10000 176100 Form 990, Part VI, Section B, Line 11b The Board of the Organization reviews the 990 prior to filing the form with the IRS. Form 990, Part VI, Section B, Line 12c Each Board Member completes a conflict-of-interest questionnaire prior to becoming a Board Member and annually thereafter. Members are required to notify the Secretary of any change during the course of the year. If anyone believes a conflict of interest may exist, the matter is referred to the Secretary for further action.Potential conflicts of interest are reviewed and discussed by the Board. Final deliberations and decisions are documented. If the Board determines that an individual has failed to comply it shall take appropriate corrective action.All Board members must sign and file their COI questionnaire annually. Form 990, Part VI, Section B, Line 15a Compensation is set by the Board of Directors. Form 990, Part VI, Section B, Line 15b Compensation is set by the Board of Directors. Form 990, Part VI, Section C, Line 19 Documents available to the public upon request.